Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years.~* Any sex.~* Type Ι or ΙΙ DM,~* recent diabetic VH which is causing vision impairment, precluding complete PRP and needing treatment.~* BCVA is less than 20/70 (log MAR BCVA 0.6) and better than 20/1000 (log MAR BCVA 1.7).~Exclusion Criteria:~* Tractional retinal detachment.~* Previous PRP.~* History of anti VEGF therapy within the past two months.~* Neovascular glaucoma~* Subhyaloid hemorrhage.~* Vitreomacular traction.~* Diabetic macular edema .~* Patients with systemic contraindications for anti VEGF or unstable medical conditions as uncontrolled hypertension (persistently above 180/110 mmhg) or recent thromboembolic event within the past six months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: ACTIVE_COMPARATOR): Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
- Group II: Early vitrectomy. (Type: ACTIVE_COMPARATOR): Early vitrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).